share_log

Karyopharm Therapeutics Q4 2023 GAAP EPS $(0.36) Misses $(0.30) Estimate, Sales $33.75M Miss $35.40M Estimate

Moomoo 24/7 ·  Feb 29 07:31

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.30) by 20 percent. The company reported quarterly sales of $33.75 million which missed the analyst consensus estimate of $35.40 million by 4.68 percent. This is a 0.50 percent increase over sales of $33.58 million the same period last year.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment